Figure 4 | Primary Care Respiratory Journal

Figure 4

From: Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients

Figure 4

Cost-effectiveness of switching from FP-SAL to efBDP-FOR, with treatment effectiveness based on exacerbation prevention (ATS/ERS definition) during the outcome year. Costs are total asthma-related healthcare costs (£/patient/year), adjusted for baseline differences

Back to article page